By Dr Rashida Hakeem, Gynaecologist, and Dr Johannah Scaffidi, Senior Registrar in Obstetrics & Gynaecology, Joondalup
Existing fertility testing primarily serves as screening tests, aiming to identify women more likely to have a poor response to Assisted Reproductive Technology (ART) and thus lower likelihood of achieving a pregnancy with treatment rather than the likelihood of spontaneous conception.
Anti-mullerian hormone (AMH) has become the mainstay of testing infertility patients, replacing the traditionally used day three FSH, oestrogen levels and antral follicle count.
It is related to the size of the primordial follicle pool and represents a marker of ovarian...
Existing fertility testing primarily serves as screening tests, aiming to identify women more likely to have a poor response to Assisted Reproductive Technology (ART) and thus lower likelihood of achieving a pregnancy with treatment rather than the likelihood of spontaneous conception.
Anti-mullerian hormone (AMH) has become the mainstay of testing infertility patients, replacing the traditionally used day three FSH, oestrogen levels and antral follicle count.
It is related to the size of the primordial follicle pool and represents a marker of ovarian...
This content is restricted to Medical Forum readers; this is a new feature. If you haven’t registered with our site in the last few weeks, please create a new account below. If you have subscribed, please log in.